Research Topics
| MARA contact LORENZISummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Defective myogenic response to posture change in retinal vessels of well-controlled type 1 diabetic patients with no retinopathyMara Lorenzi
Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114, USA
Invest Ophthalmol Vis Sci 51:6770-5. 2010..The authors sought to identify early abnormalities of retinal vessels that are not prevented by the current therapeutic approach...
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilientMara Lorenzi
Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA
Exp Diabetes Res 2007:61038. 2007....- Retinal haemodynamics in individuals with well-controlled type 1 diabetesM Lorenzi
Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, and Diabetes Center and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
Diabetologia 51:361-4. 2008..Based on this, the aim of this study was to investigate whether patients with type 1 diabetes treated entirely or mostly in the post-DCCT era and tested in the absence of confounding factors show retinal haemodynamic abnormalities... 
Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathyZeina Dagher
Harvard Medical School, Schepens Eye Research Institute, 20 Staniford St, Boston, MA 02114, USA
Diabetes 53:2404-11. 2004..Excess aldose reductase activity can be a mechanism for human diabetic retinopathy...- The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathyChiara Gerhardinger
Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
Diabetes 58:1659-67. 2009..We aimed to identify candidate drug targets by investigating the molecular effects of drugs that prevent retinal capillary demise in the diabetic rat... - Mechanisms and strategies for prevention in diabetic retinopathyMara Lorenzi
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA
Curr Diab Rep 6:102-7. 2006..The challenge for the next few years is to find ways faster than clinical trials to ascertain the relevance to human diabetic retinopathy of adjunct drugs successful in animal studies... - Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effectsWei Sun
Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, 20 Staniford St, Boston, Massachusetts 02114, USA
Diabetes 54:3418-26. 2005..Aspirin at low-intermediate concentrations selectively prevented microangiopathy. The minimal effective dose of aspirin should now be sought... - A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathyWei Sun
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford St, Boston, MA 02114, USA
Diabetes 55:2757-62. 2006.... - A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the ratVeronica Asnaghi
Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA
Diabetes 52:506-11. 2003..These findings have implications for how to evaluate the role of the polyol pathway in diabetic retinopathy... - Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytesGiulio Romeo
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA
Diabetes 51:2241-8. 2002..A proapoptotic program triggered by NF-kappaB selectively in retinal pericytes in response to hyperglycemia is a possible mechanism for the early demise of pericytes in diabetic retinopathy... - Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathyJing Zhang
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA
Diabetes 51:3499-504. 2002..These are novel clues for probing how diabetes affects and damages vascular cells...
Research Grants
- Mechanisms of action of drugs that prevent experimental diabetic retinopathyMARA contact LORENZI; Fiscal Year: 2010....
- Retinal Blood Flow and Microthrombi in Type 1 DiabetesMara Lorenzi; Fiscal Year: 2004....
- HIGH GLUCOSE, DNA, AND DIABETIC COMPLICATIONSMara Lorenzi; Fiscal Year: 2002..If a chain of causal relationships is established, the studies will bring to the fore targets for rational interventions. ..
- HIGH GLUCOSE, DNA, AND DIABETIC COMPLICATIONSMara Lorenzi; Fiscal Year: 1993..In addition, since the DNA repair mechanisms are under genetic control, the occurrence of DNA damage-repair may be envisioned to play a role in the different individual susceptibility to diabetic vascular complications...
- HIGH GLUCOSE, DNA, AND DIABETIC COMPLICATIONSMara Lorenzi; Fiscal Year: 1999..Lastly, cell cultures of retinal microvascular pericytes and endothelial cells will be used to determine whether elevated hexose can initiate apoptosis (and if so, by what mechanism) and/or have an effect on the expression of IGF-I. ..
- Mechanisms of action of drugs that prevent experimental diabetic retinopathyMARA contact LORENZI; Fiscal Year: 2010..In addition, the studies are poised to generate a paradigm for applications of anti-TGF- therapy to other pathologies. ..